Basics |
Fulgent Genetics, Inc.
Fulgent Genetics Inc is a technology company offering genetic testing to provide physicians with clinically actionable diagnostic information used to improve the overall quality of patient care.
|
IPO Date: |
September 29, 2016 |
Sector: |
Healthcare |
Industry: |
Medical Diagnostics and Research |
Market Cap: |
$550.12M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.92 | 2.94%
|
Avg Daily Range (30 D): |
$0.24 | 1.23%
|
Avg Daily Range (90 D): |
$0.34 | 1.78%
|
Institutional Daily Volume |
Avg Daily Volume: |
.3M |
Avg Daily Volume (30 D): |
.17M |
Avg Daily Volume (90 D): |
.27M |
Trade Size |
Avg Trade Size (Sh.): |
63 |
Avg Trade Size (Sh.) (30 D): |
43 |
Avg Trade Size (Sh.) (90 D): |
46 |
Institutional Trades |
Total Inst.Trades: |
1,715 |
Avg Inst. Trade: |
$1.85M |
Avg Inst. Trade (30 D): |
$.88M |
Avg Inst. Trade (90 D): |
$1.48M |
Avg Inst. Trade Volume: |
.04M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$1.98M |
Avg Closing Trade (30 D): |
$.88M |
Avg Closing Trade (90 D): |
$1.57M |
Avg Closing Volume: |
44.65K |
|
|
News |
Jul 15, 2025 @ 11:41 PM
Bragar Eagel & Squire, P.C. Is Investigating GoHea...
Source: Bragar Eagel & Squire, P.C.
|
Jul 1, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating GoHea...
Source: Bragar Eagel & Squire, P.C.
|
Jun 23, 2025 @ 4:53 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: N/A
|
Jun 10, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating Semle...
Source: N/A
|
Jun 3, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating EchoS...
Source: Bragar Eagel & Squire, P.C.
|
Financials |
|
TTM |
Q1 2025 |
Q4 2024 |
Basic EPS
|
|
|
|
Diluted EPS
|
|
|
|
Revenue
|
$ 292.45M
|
$ 73.46M
|
$ 76.21M
|
Gross Profit
|
$ 113.46M
|
$ 28.35M
|
$ 31.85M
|
Net Income / Loss
|
$ -41.87M
|
$ -11.9M
|
$ -6.19M
|
Operating Income / Loss
|
$ -71.92M
|
$ -19.8M
|
$ -16.14M
|
Cost of Revenue
|
$ 178.99M
|
$ 45.12M
|
$ 44.37M
|
Net Cash Flow
|
$ 12.74M
|
$ 12.14M
|
$ -2.9M
|
PE Ratio
|
|
|
|
|
|
|